Sodré GB Neto
@international.ufg.br
Biology
Federal University of Goias
Coordinate clinical trials. Chief editor of Jornal da Ciência . Research on microRNA for cellular precision diagnosis and more efficient microRNA treatments. Critic of the theory of evolution due to highlighting the lack of a single observation in any living being of a set of coordinated positive mutations building new systems, as falsification of the historical-paleontological theory of evolution, which prevents it from even being a scientific hypothesis. Points out errors in dating, emphasizing the presence of still organic tissues in thousands of fossils erroneously dated in millions of years and C14 in mantle diamonds, erroneously dated at 1 to 2.5 billion years, as evidence of clear geochronological error since C14 disappears in a few thousand years, and it is practically impossible for N14 to capture neutrons inside diamonds in the mantle for billions of consecutive years; Defends the "Theory of Species Degeneration" due to observ
EDUCATION
Graduated in theology from UNASP in 1992 with various specialties as detailed in the curriculum . Currently pursuing degrees in geology, biology, and biomedicine, engaged in multidisciplinary areas, and employed as a researcher at the Federal University of Goiás (UFG) in the fields of pharmacy, medicine, and biotechnology.
RESEARCH, TEACHING, or OTHER INTERESTS
Multidisciplinary, Clinical Biochemistry, Cancer Research, Biophysics
FUTURE PROJECTS
Phytotherapeutic Interventions in Acute Lymphoblastic Leukemia: miRNA Modulation as a Therapeutic Strategy.
Acute lymphoblastic leukemia (ALL) is a type of cancer that affects lymphocyte-producing cells in the bone marrow. Its diagnosis and treatment require a multidisciplinary approach, involving chemotherapy, radiotherapy, bone marrow transplantation and supportive care. MicroRNAs (miRNAs) are small non-coding RNA molecules that play a crucial role in regulating gene expression. MiRNAs have been explored as therapeutic targets in cancer treatment. They can be used to restore the function of tumor suppressor miRNAs or inhibit the activity of oncogenic miRNAs. Its unregulated expression in the body represents continuity of the disease. Recently, miRNAs from tumor cells have been detected circulating in the blood of cancer patients, representing a new opportunity to use miRNAs in blood as an early predictor of cancer, and as a marker of response to therapy and disease prognosis. The treatment of ALL based-on miRNAs by the SUS can bring significant benefits, by becoming an option in the availa
Applications Invited